A transformative chapter in cancer research is unfolding: This July marks a pivotal moment as the Asklepios Lung Clinic in Gauting becomes the newest site for our new clinical study, “Molecular Fingerprinting for Cancer Detection”. This study could redefine how we diagnose lung cancer.
Starting now, lung cancer patients and those with other lung conditions will be part of this study, potentially unlocking new insights into early cancer detection and diagnosis. In this study, researchers from the Faculty of Physics at LMU will examine the blood samples from Gauting using cutting-edge infrared spectroscopy, which offers a glimpse into the very building blocks of disease and holding the potential to transform cancer diagnostics by detecting abnormalities earlier than ever before.
This new phase of research builds on the remarkable success achieved from 2017 to 2022. During that time, our new method yielded promising results in a basic study, setting the stage for the more extensive and ambitious study now underway. The Asklepios Clinic, a key partner in the earlier study, continues to play a crucial role in this next chapter.
The momentum is building! In the coming months, top clinics across Germany will join our ambitious study, expanding our participant base and accelerating the pace of discovery – where early detection could mean the difference for countless patients.
